3 news items
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
ATXI
FBIO
16 May 24
("KOL") event highlighting expert perspectives on SBMA. The event featured Christopher Grunseich, M.D., Lasker Clinical Research Scholar
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
ATXI
FBIO
15 May 24
) In April, Avenue hosted a virtual key opinion leader ("KOL") event highlighting expert perspectives on SBMA. The event featured
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
ATXI
FBIO
25 Mar 24
, today announced that it will host a virtual key opinion leader ("KOL") event highlighting expert perspectives on spinal bulbar muscular atrophy ("SBMA
- Prev
- 1
- Next